GU Cancers 2020 | Biomarkers in RCC

VJOncology is committed to improving our service to you

Martin Voss

Martin Voss, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the main clinically useful biomarkers in renal cell carcinoma (RCC), how they can be used in decision-making, and whether why are ready from prime time. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter